Nalgesic (Fenoprofen Calcium)

Fenoprofen calcium, the active ingredient in Nalgesic, is a nonsteroidal anti-inflammatory drug presented as an oral formulation for systemic use. It is used to relieve mild to moderate pain and to reduce inflammation in conditions such as rheumatoid arthritis and osteoarthritis.

GNH USA supplies Nalgesic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nalgesic (fenoprofen calcium) is employed in the management of inflammatory and musculoskeletal disorders. - Mild to moderate pain: provides analgesic relief by reducing prostaglandin‑mediated nociception. - Rheumatoid arthritis: decreases joint inflammation, swelling and stiffness. - Osteoarthritis: alleviates chronic joint pain and improves functional mobility.

Adverse reactions may occur with any NSAID, including fenoprofen calcium.

Common Side Effects: - Gastrointestinal discomfort: dyspepsia, nausea, or abdominal pain. - Headache or dizziness. - Skin rash or pruritus.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding. - Renal impairment or acute kidney injury. - Hepatic dysfunction, including elevated transaminases. - Severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome. - Cardiovascular events, including thrombotic complications.

Before prescribing fenoprofen calcium, clinicians should consider several safety measures. - Assess renal function: evaluate baseline creatinine and eGFR. - Monitor gastrointestinal risk: avoid use in patients with a history of ulcer disease or bleeding. - Use with caution in cardiovascular disease: consider alternative NSAIDs if high thrombotic risk. - Avoid concomitant anticoagulants unless necessary: increased bleeding potential. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Fenoprofen calcium may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Selective COX‑2 inhibitors: additive renal toxicity. - Lithium: increased serum lithium concentrations. - Methotrexate: reduced renal clearance leading to toxicity. - ACE inhibitors or ARBs: potential for acute renal impairment.

Moderate Interactions (Monitor Closely): - Diuretics: possible reduction in renal perfusion. - Corticosteroids: increased risk of gastrointestinal ulceration. - SSRIs or SNRIs: modest increase in bleeding tendency.